Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the periods presented:

Three months ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2024

    

2023

    

2024

    

2023

Qbrexza

$

7,583

$

5,865

$

19,435

$

18,038

Accutane

3,996

4,882

15,534

15,109

Amzeeq

1,542

2,336

3,503

4,904

Zilxi

558

681

1,200

1,567

Other / legacy product revenue

950

1,515

2,842

4,787

Collaboration revenue

182

546

Revenue – related party

 

 

31

 

41

 

97

Other revenue

19,260

 

19,519

Total net revenue

$

14,629

$

34,752

$

42,555

$

64,567